File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.diff.2023.01.001
- Scopus: eid_2-s2.0-85147376223
- Find via
Supplementary
-
Citations:
- Scopus: 0
- Appears in Collections:
Article: T, NK, then macrophages: Recent advances and challenges in adaptive immunotherapy from human pluripotent stem cells
| Title | T, NK, then macrophages: Recent advances and challenges in adaptive immunotherapy from human pluripotent stem cells |
|---|---|
| Authors | |
| Issue Date | 1-Apr-2023 |
| Publisher | Elsevier |
| Citation | Differentiation, 2023, v. 130, p. 51-57 How to Cite? |
| Abstract | Adaptive cellular immunotherapy, especially chimeric antigen receptor-T (CAR-T) cell therapy, has advanced the treatment of hematological malignancy. However, major limitations still remain in the source of cells comes from the patients themselves. The use of human pluripotent stem cells to differentiate into immune cells, such as T cells, NK cells, and macrophages, then arm with chimeric antigen receptor (CAR) to enhance tumor killing has gained major attention. It is expected to solve the low number of immune cells recovery from patients, long waiting periods, and ethical issues(reprogramming somatic cells to produce induced pluripotent stem cells (iPS cells) avoids the ethical issues unique to embryonic stem cells (Lo and Parham, 2009). However, there are still major challenges to be further solved. This review summarizes the progress, challenges, and future direction in human pluripotent stem cell-based immunotherapy. |
| Persistent Identifier | http://hdl.handle.net/10722/331444 |
| ISSN | 2021 Impact Factor: 3.533 2020 SCImago Journal Rankings: 1.030 |
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Hang, Su | - |
| dc.contributor.author | Wang, Nan | - |
| dc.contributor.author | Sugimura, Ryohichi | - |
| dc.date.accessioned | 2023-09-21T06:55:48Z | - |
| dc.date.available | 2023-09-21T06:55:48Z | - |
| dc.date.issued | 2023-04-01 | - |
| dc.identifier.citation | Differentiation, 2023, v. 130, p. 51-57 | - |
| dc.identifier.issn | 0301-4681 | - |
| dc.identifier.uri | http://hdl.handle.net/10722/331444 | - |
| dc.description.abstract | <p>Adaptive cellular immunotherapy, especially chimeric antigen receptor-T (CAR-T) cell therapy, has advanced the treatment of hematological malignancy. However, major limitations still remain in the source of cells comes from the patients themselves. The use of human pluripotent stem cells to differentiate into <a href="https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/immunocompetent-cell" title="Learn more about immune cells from ScienceDirect's AI-generated Topic Pages">immune cells</a>, such as T cells, NK cells, and macrophages, then arm with <a href="https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/chimeric-antigen-receptor" title="Learn more about chimeric antigen receptor from ScienceDirect's AI-generated Topic Pages">chimeric antigen receptor</a> (CAR) to enhance tumor killing has gained major attention. It is expected to solve the low number of immune cells recovery from patients, long waiting periods, and ethical issues(reprogramming <a href="https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/somatic-cell" title="Learn more about somatic cells from ScienceDirect's AI-generated Topic Pages">somatic cells</a> to produce <a href="https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/induced-pluripotent-stem-cell" title="Learn more about induced pluripotent stem cells from ScienceDirect's AI-generated Topic Pages">induced pluripotent stem cells</a> (iPS cells) avoids the ethical issues unique to <a href="https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/embryonic-stem-cell" title="Learn more about embryonic stem cells from ScienceDirect's AI-generated Topic Pages">embryonic stem cells</a> (<a href="https://www.sciencedirect.com/science/article/pii/S0301468123000014?via%3Dihub#bib49">Lo and Parham, 2009</a>). However, there are still major challenges to be further solved. This review summarizes the progress, challenges, and future direction in human pluripotent stem cell-based immunotherapy.<span> </span></p> | - |
| dc.language | eng | - |
| dc.publisher | Elsevier | - |
| dc.relation.ispartof | Differentiation | - |
| dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
| dc.title | T, NK, then macrophages: Recent advances and challenges in adaptive immunotherapy from human pluripotent stem cells | - |
| dc.type | Article | - |
| dc.identifier.doi | 10.1016/j.diff.2023.01.001 | - |
| dc.identifier.scopus | eid_2-s2.0-85147376223 | - |
| dc.identifier.volume | 130 | - |
| dc.identifier.spage | 51 | - |
| dc.identifier.epage | 57 | - |
| dc.identifier.eissn | 1432-0436 | - |
| dc.identifier.issnl | 0301-4681 | - |